Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
about
Bupivacaine versus lignocaine as the choice of locall anesthetic agent for impacted third molar surgery a reviewPharmacokinetics of dihydroquinidine in congestive heart failure patients after intravenous quinidine administrationPitfalls and perils of intravenous lidocaine.Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarctionThe Smith Kline & French lecture 1987. Clinical pharmacology and the art of bespoke prescribing.Drug structure-transport relationshipsBioavailability of quinidine in congestive heart failure.Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failureAltered elimination of antipyrine in patients with acute viral hepatitis.The effects of age and liver disease on the disposition and elimination of diazepam in adult man.Lignocaine kinetics in cardiac patients and aged subjectsReduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.Lignocaine and indocyanine green kinetics in patients following myocardial infarction.Population pharmacokinetics of lidocaine administered during and after cardiac surgery.Plasma concentrations of lignocaine during fibreoptic bronchoscopy.Effect of fiberoptic bronchoscopy on respiratory performance in patients with chronic airways obstruction.Lignocaine: a new technique for intravenous administration.Antiarrhythmics: elimination and dosage considerations in hepatic impairment.Drug metabolism and liver disease in India.Part 6. Pediatric advanced life support: 2015 Korean Guidelines for Cardiopulmonary Resuscitation.Comparison of Transcutaneous Electrical Nerve Stimulation and Lidocaine on Episiotomy Complication in Primiparous Women: A Randomized Clinical TrialTumescent technique for regional anesthesia permits lidocaine doses of 35 mg/kg for liposuction.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).Surgically placed abdominal wall catheters on postoperative analgesia and outcomes after living liver donation.Effects of cardiovascular disease on pharmacokinetics.Sedation for fibreoptic bronchoscopy.Lignocaine topicalization of the pediatric airway.Lidocaine elimination and monoethylglycinexylidide formation in the dehydrated camel.The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled TrialThe pharmacokinetics of lignocaine in humans during a computer-controlled infusion.Disopyramide--an effective treatment for lignocaine resistant ventricular dysrhythmias.Drug metabolism under pathological and abnormal physiological states in animals and man.Protein binding and kinetics of drugs in liver diseases.Rational basis of antiarrhythmic therapy: clinical pharmacology of commonly used antiarrhythmic drugs.Blood levels of drugs used in the treatment of cardiac arrhythmias.Impairment of drug metabolism in patients with liver cancer.Physiologic pharmacokinetic models: relevance, experience, and future trends.Metabolism and excretion of antiarrhythmic drugs.Intravenous antiarrhythmic drugs: newer aspects of therapy.Drug disposition and liver disease.
P2860
Q28083112-1882B225-7109-4951-B190-428EC361FB84Q28328301-EDC04850-96A0-484D-93FC-E069CA562B5EQ28366967-350A0697-2DA0-487D-91AE-2D12E6D6E562Q34398010-E791C960-A27E-431E-B142-36E20ECEC6CEQ34418034-76BFB1D7-8B08-4F19-9DF1-D620CE8DEAFFQ34420259-77159D4C-EE5D-4727-AF24-B0C59BA5D954Q34450437-E1108771-1A5F-4850-A8A5-345F45D67647Q34451770-03BA046F-BA07-435C-B707-3C0CB9FDF1F3Q34471989-83EA3C1D-B054-4444-8FC4-43D0DF3823A5Q34473755-ECEEF71F-F94B-4205-A4F2-84771DF77016Q34515754-97FD7141-B9BC-458C-A9D9-2BC2CACD322BQ34517822-F748A0AE-CA39-4E6A-AE36-BB1D48BC0215Q34519147-C1FEB6FB-D6EE-4F78-A358-A98F6C32EFB6Q35464790-4D361995-5988-4668-B349-8EBB7B708F0AQ36118143-A8EF0F30-0AA1-474C-8769-6734A8DFFB1FQ36435549-14B935E7-76ED-4DF3-9C8E-DF5C91BBFF6DQ36803697-9C262274-9795-4716-83E5-2F7BDC670E31Q37008809-3B919B65-1660-4362-883D-CDABD41F2EF5Q37238161-0B8B752A-BB4C-4F68-8BA8-3BBCCD9637BEQ37315740-0EAA1644-E2A1-4929-8801-DCC0CB786B62Q37719853-1BBCD34F-98C6-495C-AF66-6741EB482FE6Q37906607-E0417334-79E8-47CC-B101-33C49AF788FBQ38076347-EB0AB543-5189-4521-B01E-58184888074DQ38302504-2DE94F79-137C-451F-80F0-38153104F699Q38378935-EC9DD487-6961-4870-865E-97A0C8838754Q38735582-3225F0D8-B86D-41DC-BBBF-951B23C88406Q38751754-2689F540-6346-4B34-97E9-3EB768598481Q38902958-C221C811-D2B2-4B30-9D9C-D35F715A84E4Q39214729-64C14FAE-D60B-4A57-BB23-3AF88DC7F29AQ39458517-2FC48849-4B2A-4F76-82AB-A03447B398DDQ39570468-F9657828-3ED8-411F-B6B4-77C9CED8AE1DQ39620103-5935D0E2-C0B1-4F5A-96BE-525EA1845D08Q39620831-94995808-D60A-4599-A2BA-4AD2D615438AQ39722587-F5C04F3D-3357-4468-BD29-A2E18FC2810CQ39793128-29CC0454-9E86-48F6-83CE-0AAB1509A11CQ40090388-E70E75F3-754A-4C45-9E31-8FBF37EA886CQ40182427-D449A787-3994-43C0-B43C-D787B3165C8EQ40200138-49F4D421-E989-4FA6-8C5B-4FFA34B93CACQ40329240-D3511D49-495F-44D8-9AC9-CE1419255A06Q40497025-7A3F54E5-B123-41D6-8523-CFCC526A7671
P2860
Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
description
1973 nî lūn-bûn
@nan
1973 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1973 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1973年の論文
@ja
1973年論文
@yue
1973年論文
@zh-hant
1973年論文
@zh-hk
1973年論文
@zh-mo
1973年論文
@zh-tw
1973年论文
@wuu
name
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@ast
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@en
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@nl
type
label
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@ast
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@en
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@nl
prefLabel
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@ast
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@en
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@nl
P2093
P1476
Lidocaine pharmacokinetics in ...... , and renal failure in humans.
@en
P2093
Richardson JA
Steinbrunn W
Thomson PD
P304
P356
10.7326/0003-4819-78-4-499
P407
P577
1973-04-01T00:00:00Z